DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 170 filers reported holding DYNE THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.62 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $34,262,743 | +20.7% | 970,891 | -2.9% | 0.43% | +14.6% |
| Q1 2024 | $28,390,000 | +159.1% | 1,000,000 | +21.4% | 0.38% | +150.7% |
| Q4 2023 | $10,959,200 | +1.9% | 824,000 | -31.3% | 0.15% | -9.1% |
| Q3 2023 | $10,752,000 | +4.8% | 1,200,000 | +31.6% | 0.16% | +11.5% |
| Q2 2023 | $10,260,000 | – | 912,000 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,220,034 | $25,574,792 | 34.99% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $57,039,011 | 23.77% |
| Atlas Venture Life Science Advisors, LLC | 9,885,449 | $113,880,372 | 15.42% |
| TCG Crossover Management, LLC | 1,650,150 | $19,009,728 | 3.70% |
| Logos Global Management LP | 1,700,000 | $19,584,000 | 2.80% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 433,751 | $4,988,137 | 1.39% |
| Octagon Capital Advisors LP | 692,945 | $7,982,726 | 1.15% |
| Deep Track Capital, LP | 2,334,633 | $26,894,972 | 1.10% |
| Altium Capital Management LP | 155,000 | $1,785,600 | 0.99% |
| HighVista Strategies LLC | 102,431 | $1,180,005 | 0.96% |